title: Effect of PGF2alpha, indomethacin, tamoxifen, or estradiol-17beta on incidence of abortion, progesterone, and pregnancy-specific protein B (PSPB) secretion in 88- to 90-day pregnant sheep.
abstract: One objective of this experiment was to evaluate our hypotheses that estradiol-17beta regulates secretion of pregnancy specific protein B (PSPB) and that secretion of progesterone during pregnancy is regulated by a prostanoid by examining the effects of prostaglandin F2alpha (PGF2alpha), a luteolyic agent; indomethacin, a prostanoid synthesis inhibitor; tamoxifen, an estrogen receptor antagonist; estradiol 17-beta; and interaction of these factors on the incidence of abortion and progesterone and PSPB secretion. Another objective was to determine if there is a luteal source of PSPB. Weights of corpora lutea were decreased (P < or = 0.05) by PGF2alpha, indomethacin, PGF2alpha + tamoxifen, PGF2alpha + indomethacin, and PGF2alpha + estradiol-17beta but not (P > or = 0.05) by tamoxifen or estradiol-17beta alone. No ewe treated with PGF2alpha alone aborted (P > or = 0.05). Forty percent of ewes treated with PGF2alpha + estradiol-17beta aborted (P < or = 0.05), but ewes were not aborted by any other treatment within the 72-h sampling period. Profiles of progesterone in jugular venous blood differed (P < or = 0.05) among control, indomethacin-, tamoxifen-, and PGF2alpha + indomethacin-treated ewes. Progesterone in jugular venous blood of control ewes decreased (P < or = 0.05) by 24 h, followed by a quadratic increase (P < or = 0.05) from 24 to 62 h. Progesterone in jugular venous blood of indomethacin-, PGF2alpha-, PGF2alpha- + tamoxifen-, PGF2alpha + indomethacin-, PGF2alpha + estradiol-17beta-, and tamoxifen-treated ewes was reduced (P < or = 0.05) by 18 h and did not vary (P > or = 0.05) for the remainder of the 72-h sampling period. Progesterone in vena cava and in uterine venous blood was reduced (P < or = 0.05) at 72 h in PGF2alpha-, indomethacin-, tamoxifen-, PGF2alpha + indomethacin-, PGF2alpha + tamoxifen-, and PGF2alpha + estradiol-17beta-treated ewes. Weights of placentomes did not differ among treatment groups (P > or = 0.05). Profiles of PSPB in inferior vena cava blood differed (P < or = 0.05) among control, estradiol-17beta-, indomethacin-, tamoxifen-, PGF2alpha + indomethacin-, and PGF2alpha + tamoxifen-treated 88- to 90-day pregnant ewes. Concentrations of PSPB in inferior vena cava blood were increased (P < or = 0.05) in indomethacin-, estradiol-17beta-, tamoxifen-, PGF2alpha + tamoxifen-, and PGF2alpha + indomethacin-treated 88- to 90-day pregnant ewes within 6 h and did not vary (P > or = 0.05) for the remainder of the 72-h sampling period. Concentrations of PSPB in uterine venous blood of indomethacin-, tamoxifen-, PGF2alpha + tamoxifen-, and PGF2alpha + indomethacin-treated ewes were greater (P < or = 0.05) at 72 h than at 0 h. PSPB in ovarian venous blood did not differ (P > or = 0.05) adjacent or opposite to the ovary with the corpus luteum. It is concluded from these data that estrogen regulates placental secretion of PSPB and that a prostanoid, presumably prostaglandin E, regulates placental secretion of progesterone during 88-90 days of gestation in sheep and that there is no luteal source of PSPB.
authors.affiliation: Department of Animal Science, University of Hawaii, Honolulu 96822, USA.
authors.forename: P J
authors.initials: PJ
authors.lastname: Bridges
authors.forename: Y S
authors.initials: YS
authors.lastname: Weems
authors.forename: L M
authors.initials: LM
authors.lastname: Kim
authors.forename: R G
authors.initials: RG
authors.lastname: Sasser
authors.forename: B R
authors.initials: BR
authors.lastname: LeaMaster
authors.forename: D L
authors.initials: DL
authors.lastname: Vincent
authors.forename: C W
authors.initials: CW
authors.lastname: Weems
mesh_terms: D000021:Abortifacient Agents, Steroidal / Q000494:pharmacology*; D000028:Abortion, Induced / Q000662:veterinary; D000034:Abortion, Veterinary; D000818:Animals; D016282:Aspartic Acid Endopeptidases / Q000097:blood*; D003338:Corpus Luteum / Q000187:drug effects / Q000378:metabolism; D015237:Dinoprost / Q000494:pharmacology*; D004958:Estradiol / Q000494:pharmacology*; D005260:Female; D005865:Gestational Age; D007213:Indomethacin / Q000494:pharmacology*; D009929:Organ Size / Q000187:drug effects; D010920:Placenta / Q000378:metabolism; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000097:blood*; D011374:Progesterone / Q000097:blood; D012756:Sheep; D013629:Tamoxifen / Q000494:pharmacology*; D015149:Tocolytic Agents / Q000494:pharmacology*; D014599:Uterus / Q000737:chemistry
chemical_list: D000021:Abortifacient Agents, Steroidal; D011257:Pregnancy Proteins; D015149:Tocolytic Agents; D013629:Tamoxifen; D011374:Progesterone; D004958:Estradiol; D015237:Dinoprost; D016282:Aspartic Acid Endopeptidases; C094766:pregnancy-associated glycoprotein 1; D007213:Indomethacin